Indena Completes Registration of Escin
pharmatechoutlook

Indena Completes Registration of Escin

By Pharma Tech Outlook | Wednesday, June 03, 2020

The company will celebrate its 100th anniversary in 2021 after establishing itself as the global leader in the identification, development, and production of active principles derived from plants, for use in the pharmaceutical, health food, and personal care industries

FREMONT, CA: Italian pharma tech giant Indena continues to improve the supply chain of Escin and Horse Chestnut derivatives after completing the registration of ESCIN (INCI: ESCIN; EC # 229-880-6, CAS # 6805-41-0, Registration 01-2120757334-53-0000) in accordance with the REACH regulation (EC) No 1907/2006 as the lead registrant. Following the pre-registration stage, which ended in 2018, Indena is the only company to complete the full registration.

Indena has made huge technological strides and further strengthened its expertise in CDMO services for active pharmaceutical ingredients (APIs) and highly potent APIs (HPAPIs) either from synthetic, fermentation, and natural origin. “The biggest pain point in the industry we try to solve is the difficulty in the supply chain plus the barriers that are represented by the need to combine different manufacturing technologies and expertise,” says Stefano Togni, business development director at Indena. The company will celebrate its 100th anniversary in 2021 after establishing itself as the global leader in the identification, development, and production of active principles derived from plants, for use in the pharmaceutical, health food, and personal care industries.

Indena has generated the relevant data, including the complex chemical characterization, fully developed the technical dossier, and successfully managed the submission of the registration dossier to ECHA. “Escin and Horse Chestnut derivatives are of strategic importance in the realm of botanical active ingredients, being used in some of the best-selling products both in the Pharmaceutical and Personal Care markets. The full characterization presented at ECHA uniquely describes our product," said Elena Uberti for Indena REACH Project. Indena was recognized as one of the Top 10 CMOs-2019 by Pharma Tech Outlook Magazine.

The Horse Chestnut derivatives market is not a commodity-like arena, due to the necessary high-quality standards and analytical complexity of its products. With this registration, Indena reconfirms its global leadership in the segment, able to guarantee the highest expertise in sourcing, manufacturing and releasing Horse Chestnut derivatives. Indena is currently expanding its portfolio of services by improving the flexibility of its multi-purpose fermentation department and launching a brand new pilot pharmaceutical plant, to efficiently serve new clinical developments and commercial projects requiring productions in the range of hundreds of kg supply.

Weekly Brief

Read Also